Marta Skoczyńska
Marta Skoczyńska has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Anna Skoczyńska
Department of Internal and Occupational Medicine and Hypertension, Wroclaw Medical University, Wroclaw, Poland
4 shared publications Barbara Turczyn
Department of Internal and Occupational Medicine and Hypertension, Wroclaw Medical University, Wroclaw, Poland
3 shared publications- Katarzyna Gruszecka
Wroclaw University of Science and Technology
3 shared publications Piotr Wiland
Department and Clinic of Rheumatology and Internal Medicine, Wroclaw Medical University, Poland
3 shared publicationsAnna Panejko
2 shared publicationsAnna Wojakowska
Department of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Borowska 213, 51-556 Wroclaw, Poland
2 shared publications
Latest Publications
- 12 January 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (3) , 320-328
Lupus mastitis heralding macrophage activation syndrome: Case report and systematic review of the literature
Objective: The purpose of this systematic review study was to showcase diagnostic challenges posed by lupus mastitis (LM). Methods: Here we report a case of a 47-year- old Caucasian female with LM heralding systemic lupus erythematosus (SLE) complicated by macrophage activation syndrome (MAS), in the light of a systematic review of the literature on LM. Results: Including our patient, we identified 32 case reports of patients with LM in the course of SLE. Only in 6 cases, including ours, LM preceded SLE diagnosis. Ours is the first ever published case report of LM heralding MAS. Conclusion: LM in the course of SLE is rare and published data is very limited. Diagnosis should be made combining physical exam, laboratory tests, imaging and histology results, and include differentiation from other autoimmune, malignant and infectious causes. Based on the reviewed literature, it is advised to consider minimally invasive core biopsies in lupus patients over open biopsies as the associated trauma may exacerbate local inflammation. Conservative treatment with immunosupressive and anti-inflammatory drugs allows for control of breast symptoms in most cases.
- 12 January 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (3) , 320-328
Lupus mastitis heralding macrophage activation syndrome: Case report and systematic review of the literature
Objective: The purpose of this systematic review study was to showcase diagnostic challenges posed by lupus mastitis (LM). Methods: Here we report a case of a 47-year- old Caucasian female with LM heralding systemic lupus erythematosus (SLE) complicated by macrophage activation syndrome (MAS), in the light of a systematic review of the literature on LM. Results: Including our patient, we identified 32 case reports of patients with LM in the course of SLE. Only in 6 cases, including ours, LM preceded SLE diagnosis. Ours is the first ever published case report of LM heralding MAS. Conclusion: LM in the course of SLE is rare and published data is very limited. Diagnosis should be made combining physical exam, laboratory tests, imaging and histology results, and include differentiation from other autoimmune, malignant and infectious causes. Based on the reviewed literature, it is advised to consider minimally invasive core biopsies in lupus patients over open biopsies as the associated trauma may exacerbate local inflammation. Conservative treatment with immunosupressive and anti-inflammatory drugs allows for control of breast symptoms in most cases.
- Open Access
- 26 August 2025
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 135 (7-8)
TB or not TB: the clinical context must give us pause
DOI: 10.20452/pamw.17099, Published online: August 26, 2025, Authors: Marta Skoczyńska1, Anna Panejko1, Katarzyna Gruszecka1,2
- 26 August 2025
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 135 (7-8)
Open AccessTB or not TB: the clinical context must give us pause
DOI: 10.20452/pamw.17099, Published online: August 26, 2025, Authors: Marta Skoczyńska1, Anna Panejko1, Katarzyna Gruszecka1,2
- Open Access
- 22 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5172
Placental Pathology in Obstetric Antiphospholipid Syndrome Beyond Thrombosis: A Case Report and Literature Review
Background: Antiphospholipid syndrome (APS) is one of the highest risk factors for obstetric complications. This article contains a case report of a patient with obstetric APS who experienced fetal loss during their first pregnancy and experienced a successful second pregnancy upon treatment with acetylsalicylic acid (ASA), low-molecular-weight heparin (LMWH), and hydroxychloroquine (HCQ). We compare placental pathology in these two pregnancies and discuss the impact of antiphospholipid antibodies and clinical management on pregnancy outcomes. We also propose methods to monitor obstetric antiphospholipid syndrome (OAPS) patients during pregnancy. Methods: A 26-year-old woman presented with a history of stillbirth at 25 weeks of pregnancy due to placental insufficiency. Before pregnancy, she experienced symptoms suggestive of autoimmune disease (thrombocytopenia, recurrent mouth aphthous ulcers, and Raynaud’s phenomenon) but had no diagnosis. Placental dysfunction correlated with the high ratio of sFlt-1/PIGF (soluble fms-like tyrosine kinase 1 and the placental growth factors index). Laboratory tests revealed the presence of antinuclear antibodies (ANAs) and triple positivity for antiphospholipid antibodies (aPLs). Results: Following the initiation of treatment for OAPS and regular monitoring consistent with current guidelines, the patient conceived and successfully delivered a healthy child. Conclusions: Adequate therapy and close monitoring during pregnancy, including clinical observation, placental biomarkers and regular ultrasonography, may help to reduce the risks and increase chances for optimal pregnancy outcomes. Additionally, pathological examination and clinical collaboration are essential components in future pregnancy counseling and should be a part of multidisciplinary management.
- 22 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5172
Open AccessPlacental Pathology in Obstetric Antiphospholipid Syndrome Beyond Thrombosis: A Case Report and Literature Review
Background: Antiphospholipid syndrome (APS) is one of the highest risk factors for obstetric complications. This article contains a case report of a patient with obstetric APS who experienced fetal loss during their first pregnancy and experienced a successful second pregnancy upon treatment with acetylsalicylic acid (ASA), low-molecular-weight heparin (LMWH), and hydroxychloroquine (HCQ). We compare placental pathology in these two pregnancies and discuss the impact of antiphospholipid antibodies and clinical management on pregnancy outcomes. We also propose methods to monitor obstetric antiphospholipid syndrome (OAPS) patients during pregnancy. Methods: A 26-year-old woman presented with a history of stillbirth at 25 weeks of pregnancy due to placental insufficiency. Before pregnancy, she experienced symptoms suggestive of autoimmune disease (thrombocytopenia, recurrent mouth aphthous ulcers, and Raynaud’s phenomenon) but had no diagnosis. Placental dysfunction correlated with the high ratio of sFlt-1/PIGF (soluble fms-like tyrosine kinase 1 and the placental growth factors index). Laboratory tests revealed the presence of antinuclear antibodies (ANAs) and triple positivity for antiphospholipid antibodies (aPLs). Results: Following the initiation of treatment for OAPS and regular monitoring consistent with current guidelines, the patient conceived and successfully delivered a healthy child. Conclusions: Adequate therapy and close monitoring during pregnancy, including clinical observation, placental biomarkers and regular ultrasonography, may help to reduce the risks and increase chances for optimal pregnancy outcomes. Additionally, pathological examination and clinical collaboration are essential components in future pregnancy counseling and should be a part of multidisciplinary management.
- 24 April 2025
- Published by Springer Nature
- p. 103-112
A Survey of Machine Learning Methods for Analyzing Synovitis Arthritis in Human Joints
- 24 April 2025
- Published by Springer Nature
- p. 103-112
A Survey of Machine Learning Methods for Analyzing Synovitis Arthritis in Human Joints
- Open Access
- 6 December 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (4) , 631-638
Usefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis
Methotrexate (MTX) is recommended as a first-line treatment for rheumatoid arthritis (RA). There are no strict guidelines regarding monitoring for liver damage in RA patients. This study aimed to evaluate noninvasive diagnostic procedures in assessing liver fibrosis in RA patients. Ninety-six RA patients were recruited for this study. The procollagen III N-terminal peptide (PIIINP) serum level was measured in all patients. The Enhanced Liver Fibrosis score (ELF-1) was calculated for 82 patients. Transient elastography (TE) was performed in 91 patients, those examined were divided into two groups: a study and control group, comprising patients with and without risk factors for liver fibrosis, respectively. The TE result correlated only with the body mass index—BMI (p < 0.05); there was no correlation with the cumulative MTX dose (p = 0.33). The TE result was significantly higher in those with risk factors for liver fibrosis than in those without risk factors (TE result > = 7.1 kPa 28/42 vs 13/41, HR = 2.103, Mann–Whitney U test, approximately 0.02). There was a positive correlation between the PIIINP level and body weight (p = 0.028), cumulative MTX dose (p = 0.007), RA activity (p = 0.028) and diabetes mellitus (DM) (p = 0.001). There was a positive correlation between the ELF-1 score and age (p < 0.001), cumulative MTX dose (p = 0.007) and RA activity (p < 0.001). The PIIINP level and ELF-1 score are not organ specific, and readings may vary depending on RA activity. TE is organ specific and can be performed by a skilled ultrasonographer might be useful to assess actual liver condition.
- 6 December 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (4) , 631-638
Open AccessUsefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis
Methotrexate (MTX) is recommended as a first-line treatment for rheumatoid arthritis (RA). There are no strict guidelines regarding monitoring for liver damage in RA patients. This study aimed to evaluate noninvasive diagnostic procedures in assessing liver fibrosis in RA patients. Ninety-six RA patients were recruited for this study. The procollagen III N-terminal peptide (PIIINP) serum level was measured in all patients. The Enhanced Liver Fibrosis score (ELF-1) was calculated for 82 patients. Transient elastography (TE) was performed in 91 patients, those examined were divided into two groups: a study and control group, comprising patients with and without risk factors for liver fibrosis, respectively. The TE result correlated only with the body mass index—BMI (p < 0.05); there was no correlation with the cumulative MTX dose (p = 0.33). The TE result was significantly higher in those with risk factors for liver fibrosis than in those without risk factors (TE result > = 7.1 kPa 28/42 vs 13/41, HR = 2.103, Mann–Whitney U test, approximately 0.02). There was a positive correlation between the PIIINP level and body weight (p = 0.028), cumulative MTX dose (p = 0.007), RA activity (p = 0.028) and diabetes mellitus (DM) (p = 0.001). There was a positive correlation between the ELF-1 score and age (p < 0.001), cumulative MTX dose (p = 0.007) and RA activity (p < 0.001). The PIIINP level and ELF-1 score are not organ specific, and readings may vary depending on RA activity. TE is organ specific and can be performed by a skilled ultrasonographer might be useful to assess actual liver condition.
- Open Access
- 19 April 2021
- Published by Springer Nature in Exposure and Health
- Vol. 13 (3) , 403-418
Exposure to Arsenic in the Air and 15-F2t-Isoprostane in Urine in a Sub-population of Inhabitants of a Copper Smelter Region
Most studies on arsenic toxicity have been conducted among populations exposed to arsenic contained in drinking water. Relatively little research concerns effects of airborne arsenic. The aim of this study was to determine whether there is an association between urinary 15-F2t-isoprostane (u15-F2t-IsoP) levels in relation to renal function (urinary creatinine and N-acetyl-β-d-glucosaminidase––uNAG) and urinary arsenic (uAs) in inhabitants from copper smelter impact zone. The secondary purpose of the analysis was to assess utility of a potential association between uAs and u15-F2t-IsoP as a biomarker of systemic oxidative stress. Urinary 15-F2t-IsoP, NAG, and creatinine were measured in 967 urine samples collected from 649 adult women (51.9 ± 13.2 years old) and 318 adult men (53.8 ± 14.9 years old). Total uAs concentration was measured in 918 samples using HPLC-ICP-MS. Arsenic species, such as inorganic arsenic, methylarsonic acid, dimethylarsinic acid, and arsenobetaine, were measured in urine collected from 255 participants with uAs exceeding the upper norm. Data were analyzed using multivariate linear regression and logistic regression models. In the studied population urinary creatinine was positively associated with uAs. A positive linear correlation (p < 0.0000) between lg(uAs) and u15-F2t-IsoP was found both for normal and elevated uAs. A positive linear correlation was observed also between lg(ΣuAs) and u15-F2t-IsoP (p < 0.0000). In the logistic regression model, after adjustment for confounders, elevated uAs was the only predictor of increased u15-F2t-IsoP (OR = 1.31, 95% CI 1.08–1.59,p < 0.01). Cigarette smoking was associated with renal proximal tubular dysfunction only in people with uNAG concentration above 75th quartile. In the studied population chronically exposed to airborne arsenic, increase in urinary arsenic is associated with renal dysfunction and systemic oxidative stress. Urinary 15-F2t-isoprostane may be useful in the monitoring of health status in populations exposed to airborne arsenic.
- 19 April 2021
- Published by Springer Nature in Exposure and Health
- Vol. 13 (3) , 403-418
Open AccessExposure to Arsenic in the Air and 15-F2t-Isoprostane in Urine in a Sub-population of Inhabitants of a Copper Smelter Region
Most studies on arsenic toxicity have been conducted among populations exposed to arsenic contained in drinking water. Relatively little research concerns effects of airborne arsenic. The aim of this study was to determine whether there is an association between urinary 15-F2t-isoprostane (u15-F2t-IsoP) levels in relation to renal function (urinary creatinine and N-acetyl-β-d-glucosaminidase––uNAG) and urinary arsenic (uAs) in inhabitants from copper smelter impact zone. The secondary purpose of the analysis was to assess utility of a potential association between uAs and u15-F2t-IsoP as a biomarker of systemic oxidative stress. Urinary 15-F2t-IsoP, NAG, and creatinine were measured in 967 urine samples collected from 649 adult women (51.9 ± 13.2 years old) and 318 adult men (53.8 ± 14.9 years old). Total uAs concentration was measured in 918 samples using HPLC-ICP-MS. Arsenic species, such as inorganic arsenic, methylarsonic acid, dimethylarsinic acid, and arsenobetaine, were measured in urine collected from 255 participants with uAs exceeding the upper norm. Data were analyzed using multivariate linear regression and logistic regression models. In the studied population urinary creatinine was positively associated with uAs. A positive linear correlation (p < 0.0000) between lg(uAs) and u15-F2t-IsoP was found both for normal and elevated uAs. A positive linear correlation was observed also between lg(ΣuAs) and u15-F2t-IsoP (p < 0.0000). In the logistic regression model, after adjustment for confounders, elevated uAs was the only predictor of increased u15-F2t-IsoP (OR = 1.31, 95% CI 1.08–1.59,p < 0.01). Cigarette smoking was associated with renal proximal tubular dysfunction only in people with uNAG concentration above 75th quartile. In the studied population chronically exposed to airborne arsenic, increase in urinary arsenic is associated with renal dysfunction and systemic oxidative stress. Urinary 15-F2t-isoprostane may be useful in the monitoring of health status in populations exposed to airborne arsenic.
- Open Access
- 19 April 2021
- Published by PAGEPress Publications in Reumatismo
- Vol. 73 (1) , 64-66
The role of PET in a clinically silent and ultrasound negative synovitis in the course of rheumatoid arthritis - a case report
We present a case report of a rheumatoid arthritis patient, who underwent a PET scan, which revealed inflammation of multiple joints, which was missed by both physical and ultrasound examinations. A 55-year old woman with a long-term rheumatoid arthritis, who had undergone arthroplasty of the left knee in the past, consulted with the rheumatologist for pain in the left knee. The physical examination revealed signs of inflammation in the left knee and right elbow. The inflammatory parameters were high. Ultrasound showed intraarticular effusion without signs of active synovitis in the left knee. The ultrasound assessment of the other joints (hands, wrists and feet) was also negative for active synovitis, while positron-emission tomography (PET) revealed increased glucose metabolism at the level of the medial side of the left knee, left radio-ulno-carpal joint, I-II-III metacarpo-phalangeal joints bilaterally, right II metatarso-phalangeal joint, and left II-III metatarso-phalangeal joints. This case report demonstrates that PET might be more sensitive than ultrasound in detecting subclinical joint inflammation.
- 19 April 2021
- Published by PAGEPress Publications in Reumatismo
- Vol. 73 (1) , 64-66
Open AccessThe role of PET in a clinically silent and ultrasound negative synovitis in the course of rheumatoid arthritis - a case report
We present a case report of a rheumatoid arthritis patient, who underwent a PET scan, which revealed inflammation of multiple joints, which was missed by both physical and ultrasound examinations. A 55-year old woman with a long-term rheumatoid arthritis, who had undergone arthroplasty of the left knee in the past, consulted with the rheumatologist for pain in the left knee. The physical examination revealed signs of inflammation in the left knee and right elbow. The inflammatory parameters were high. Ultrasound showed intraarticular effusion without signs of active synovitis in the left knee. The ultrasound assessment of the other joints (hands, wrists and feet) was also negative for active synovitis, while positron-emission tomography (PET) revealed increased glucose metabolism at the level of the medial side of the left knee, left radio-ulno-carpal joint, I-II-III metacarpo-phalangeal joints bilaterally, right II metatarso-phalangeal joint, and left II-III metatarso-phalangeal joints. This case report demonstrates that PET might be more sensitive than ultrasound in detecting subclinical joint inflammation.
- 27 January 2021
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 40 (8) , 1308-1319
Urinary leucine aminopeptidase 3 in population environmentally exposed to airborne arsenic
Introduction: Environmental arsenic contamination is a major toxicological problem worldwide due to its carcinogenic and nephrotoxic potential. Aim: The purpose of this observational study was to determine the suspected association between urinary arsenic (uAs) and urinary leucine (or leucyl) aminopeptidase 3 (uLAP3) to evaluate uLAP3 as a candidate biomarker of exposure to airborne arsenic. Materials and Methods: A total of 918 adults occupationally and/or environmentally exposed to airborne arsenic were enrolled in the study. Baseline information (age; sex; history of smoking; alcohol, fish and seafood consumption) was gathered. Total uAs concentrations [μg/L] of 918 subjects, as well as the sum of arsenic species (ΣiAs) in 259 subjects, were obtained. Urinary LAP3 was measured by an immune-enzymatic assay using an ELISA kit. Urinary creatinine concentration was assessed with the IB/lAB/1289 research protocol (version II, 2015-09-17). The values of uAs and uLAP3 were recalculated per unit of creatinine. The association between uAs and uLAP3 was assessed using a logistic regression model adjusted for confounders. Results: The study identified a positive correlation between the logarithm of uAs and the logarithm of uLAP3 in the study population (r = 0.1737, p < 0.0000) and between urinary creatinine and uLAP3 concentration not adjusted for creatinine level (r = 0.1871, p < 0.001). In the logistic regression model, there was also an association between increased (≥15 µg/L) uAs and decreased (below the 25th quartile) uLAP3 [OR uLAP3 = 1.22 (95% CI 1.03 to 1.44, p < 0.02)]. Conclusions: These data suggest that urinary LAP3 may be a potential biomarker of arsenic exposure, which warrants further study.
- 27 January 2021
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 40 (8) , 1308-1319
Urinary leucine aminopeptidase 3 in population environmentally exposed to airborne arsenic
Introduction: Environmental arsenic contamination is a major toxicological problem worldwide due to its carcinogenic and nephrotoxic potential. Aim: The purpose of this observational study was to determine the suspected association between urinary arsenic (uAs) and urinary leucine (or leucyl) aminopeptidase 3 (uLAP3) to evaluate uLAP3 as a candidate biomarker of exposure to airborne arsenic. Materials and Methods: A total of 918 adults occupationally and/or environmentally exposed to airborne arsenic were enrolled in the study. Baseline information (age; sex; history of smoking; alcohol, fish and seafood consumption) was gathered. Total uAs concentrations [μg/L] of 918 subjects, as well as the sum of arsenic species (ΣiAs) in 259 subjects, were obtained. Urinary LAP3 was measured by an immune-enzymatic assay using an ELISA kit. Urinary creatinine concentration was assessed with the IB/lAB/1289 research protocol (version II, 2015-09-17). The values of uAs and uLAP3 were recalculated per unit of creatinine. The association between uAs and uLAP3 was assessed using a logistic regression model adjusted for confounders. Results: The study identified a positive correlation between the logarithm of uAs and the logarithm of uLAP3 in the study population (r = 0.1737, p < 0.0000) and between urinary creatinine and uLAP3 concentration not adjusted for creatinine level (r = 0.1871, p < 0.001). In the logistic regression model, there was also an association between increased (≥15 µg/L) uAs and decreased (below the 25th quartile) uLAP3 [OR uLAP3 = 1.22 (95% CI 1.03 to 1.44, p < 0.02)]. Conclusions: These data suggest that urinary LAP3 may be a potential biomarker of arsenic exposure, which warrants further study.
- Open Access
- 29 October 2020
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 58 (5) , 312-323
Pathophysiology of hyperuricemia and its clinical significance – a narrative review
Hyperuricemia, i.e. increased serum uric acid (UA) concentration, is a common problem in clinical practice. While there are clear guidelines concerning management of symptomatic hyperuricemia in acute conditions such as gout, urolithiasis or acute urate nephropathy, less is known about their secondary prevention. Moreover, despite the ongoing debate on the role of UA in the pathogenesis of chronic kidney disease, hypertension, cardiovascular disease and heart failure, the management of asymptomatic hyperuricemia in patients with these chronic conditions is still mainly up to physicians’ judgement. Individual considerations should always be taken into account when prescribing urate-lowering therapy. In this narrative review study, we attempt to present current trends concerning treatment of patients with either symptomatic or asymptomatic hyperuricemia in the light of the available knowledge on the role of hyperuricemia in the development of gout, renal, cardiovascular and other diseases.
- 29 October 2020
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 58 (5) , 312-323
Open AccessPathophysiology of hyperuricemia and its clinical significance – a narrative review
Hyperuricemia, i.e. increased serum uric acid (UA) concentration, is a common problem in clinical practice. While there are clear guidelines concerning management of symptomatic hyperuricemia in acute conditions such as gout, urolithiasis or acute urate nephropathy, less is known about their secondary prevention. Moreover, despite the ongoing debate on the role of UA in the pathogenesis of chronic kidney disease, hypertension, cardiovascular disease and heart failure, the management of asymptomatic hyperuricemia in patients with these chronic conditions is still mainly up to physicians’ judgement. Individual considerations should always be taken into account when prescribing urate-lowering therapy. In this narrative review study, we attempt to present current trends concerning treatment of patients with either symptomatic or asymptomatic hyperuricemia in the light of the available knowledge on the role of hyperuricemia in the development of gout, renal, cardiovascular and other diseases.
- 6 April 2020
- Published by SAGE Publications in Lupus
- Vol. 29 (6) , 631-639
Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature
Objective: The purpose of this study was to characterize the role of eculizumab, a monoclonal antibody against the terminal complement component C5, in patients with catastrophic antiphospholipid syndrome (CAPS). Methods: We present a case report of a patient with systemic lupus erythematosus (SLE) and CAPS treated with eculizumab, as well as results of a systematic review of the literature. Results: Including our patient, we identified 11 case reports of patients with CAPS treated with eculizumab. All of them had partial or total remission of symptoms. Conclusion: Data on eculizumab efficacy in CAPS are promising but are limited to single case reports. More studies are needed to develop evidence-based recommendations for eculizumab use in CAPS.
- 6 April 2020
- Published by SAGE Publications in Lupus
- Vol. 29 (6) , 631-639
Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature
Objective: The purpose of this study was to characterize the role of eculizumab, a monoclonal antibody against the terminal complement component C5, in patients with catastrophic antiphospholipid syndrome (CAPS). Methods: We present a case report of a patient with systemic lupus erythematosus (SLE) and CAPS treated with eculizumab, as well as results of a systematic review of the literature. Results: Including our patient, we identified 11 case reports of patients with CAPS treated with eculizumab. All of them had partial or total remission of symptoms. Conclusion: Data on eculizumab efficacy in CAPS are promising but are limited to single case reports. More studies are needed to develop evidence-based recommendations for eculizumab use in CAPS.